SU5416 and Paclitaxel in Treating Patients With Advanced Cancer

NCT ID: NCT00006257

Last Updated: 2010-01-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2000-11-30

Brief Summary

RATIONALE: Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining SU5416 with chemotherapy may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining SU5416 and paclitaxel in treating patients who have advanced cancer.

Detailed Description

OBJECTIVES:

• Determine the maximum tolerated dose of SU5416 when combined with paclitaxel in patients with advanced malignancies.
• Determine the toxicities and pharmacokinetics of this regimen in these patients.
• Determine the effects of this regimen on a variety of histological and molecular biomarkers of angiogenesis, including in vitro activity assays of endothelial cell proliferation, migration, and invasion.

OUTLINE: This is a dose escalation study of SU5416.

Patients receive SU5416 IV over 1 hour twice weekly during the first week. During subsequent courses, SU5416 is administered on days 1, 4, 8, 11, 15, 18, 22, and 25. Paclitaxel begins on the second week of therapy and is administered IV over 1 hour on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of SU5416 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.

PROJECTED ACCRUAL: Approximately 24 patients will be accrued for this study within 12-18 months.

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Study Design

• Primary Study Purpose: TREATMENT

Interventions

paclitaxel

Intervention Type: DRUG

semaxanib

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically proven advanced malignancy for which no satisfactory treatment exists
• Must have tumor accessible by biopsy

• Minimum of 1 baseline biopsy required
• No brain metastases or primary CNS tumor

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• WHO 0-2

Life expectancy:

• At least 3 months

Hematopoietic:

• Absolute neutrophil count at least 1,500/mm3
• Platelet count at least 100,000/mm3

Hepatic:

• SGOT and SGPT less than 2 times upper limit of normal unless due to presence of tumor
• Bilirubin normal

Renal:

• Creatinine no greater than 1.5 mg/dL
• Creatinine clearance greater than 60 mL/min

Cardiovascular:

• No uncompensated coronary artery disease by ECG or physical examination
• No myocardial infarction or severe unstable/angina within the past 6 months
• No severe peripheral vascular disease associated with diabetes mellitus
• No severe deep vein or arterial thrombosis within the past 3 months

Pulmonary:

• No pulmonary embolism within the past 3 months

Other:

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No unstable or severe concurrent medical condition
• No active uncontrolled infection
• No history of allergic reaction to paclitaxel or Cremophor
• No greater than grade 1 peripheral neuropathy

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No prior SU5416

Chemotherapy:

• No prior paclitaxel
• Greater than 4 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin) and recovered

Endocrine therapy:

• Not specified

Radiotherapy:

• Greater than 4 weeks since prior radiotherapy and recovered

Surgery:

• See Disease Characteristics

Other:

• Recovered from any prior investigational agents
• No other concurrent investigational agents

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

City of Hope Medical Center

OTHER

Sponsor Role: lead

Principal Investigators

Przemyslaw W. Twardowski, MD

Role: STUDY_CHAIR

City of Hope Comprehensive Cancer Center

Locations

Cancer Center and Beckman Research Institute, City of Hope

Duarte, California, United States

USC/Norris Comprehensive Cancer Center and Hospital

Los Angeles, California, United States

University of California Davis Cancer Center

Sacramento, California, United States

Countries

United States

Other Identifiers

U01CA062505

Identifier Type: NIH

Identifier Source: secondary_id

View Link

P30CA033572

Identifier Type: NIH

Identifier Source: secondary_id

View Link

CHNMC-PHI-30

Identifier Type: -

Identifier Source: secondary_id

CHNMC-IRB-99098

Identifier Type: -

Identifier Source: secondary_id

NCI-T99-0086

Identifier Type: -

Identifier Source: secondary_id

CDR0000068191

Identifier Type: -

Identifier Source: org_study_id